EUVIMEDEUVIMED entdecken
Crossref

Antimalarials in systemic lupus erythematosus: benefits beyond disease activity

Rosa M Andrade, Graciela S Alarcón

Future Rheumatology · 2006-04 · 1 (2) · 225-233

DOI: 10.2217/17460816.1.2.225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Rheumatology, 2006-04. Verfasst von Rosa M Andrade und 1 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimalarials, particularly hydroxychloroquine, have proven beneficial effects beyond the control of disease activity among systemic lupus erythematosus patients. Indeed, recent data support the notion that prolonged treatment with hydroxychloroquine prevents damage accrual. Furthermore, this protective effect may expand to increased survival. Although toxicity remains a concern, it is rare and should not prevent practitioners from recommending hydroxychloroquine to all lupus patients, including children and pregnant women. Adequate ophthalmological monitoring and dosing should take place.

Zitieren

APA

Andrade, R. M., & Alarcón, G. S. (2006). Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatology, 1(2), 225-233. https://doi.org/10.2217/17460816.1.2.225

Vancouver

Andrade RM, Alarcón GS. Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatology. 2006;1(2):225-233. doi:10.2217/17460816.1.2.225

BibTeX
@article{Andrade2006,
  author = {Andrade, Rosa M and Alarcón, Graciela S},
  title = {Antimalarials in systemic lupus erythematosus: benefits beyond disease activity},
  journal = {Future Rheumatology},
  year = {2006},
  volume = {1},
  number = {2},
  pages = {225--233},
  doi = {10.2217/17460816.1.2.225}
}
Kostenlos starten →